Please ensure Javascript is enabled for purposes of website accessibility

Novavax Will Seek a Combo Vaccine for Flu and COVID-19

By Taylor Carmichael – Oct 13, 2020 at 2:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has tasked a team of executives first with getting its flu vaccine candidate approved, and then with combining it with the coronavirus vaccine that it's developing.

While Novavax (NVAX -2.88%) is racing to bring its coronavirus vaccine candidate to market as fast as possible, the company is also planning for a post-pandemic future. "I am excited about the potential to develop a combined influenza/COVID-19 vaccine for use after the pandemic," said Chief Executive Officer Stanley Erck in a news release Tuesday to announce the formation of a leadership team to move its flu vaccine candidate, Nanoflu, through the regulatory approval process.

Back in March, the vaccine specialist found success with its phase 3 trial for Nanoflu, but that good news was somewhat swamped by the urgency of finding a vaccine for COVID-19. Novavax's candidate in that effort, NVX-CoV2373, has been zooming through the development process at a rapid pace, and is being tested in multiple trials, including a phase 2 trial in Australia and the U.S., a phase 2 trial in South Africa, and a 10,000 person phase 3 trial in the U.K. Another phase 3 trial involving 30,000 volunteers is planned for the U.S.

Mock-up image of vaccine shot, plus a doctor and an image of a COVID-19 molecule

Image source: Getty Images

But because of the world's dire need for an effective COVID-19 vaccine, the company's flu vaccine program has made little progress since its phase 3 trial. CFO John Trizzino recently suggested that the company would not file its biologics license application for NanoFlu until the end of 2021.

Tuesday's announcement reflects Novavax's desire to accelerate the NanoFlu program and get its vaccine to market faster. Executive Vice President Rip Wilson was put in charge of the program. He is joined by Dr. Vivek Shinde and Dr. Tim Hahn, veterans of NanoFlu's development. The team will also oversee the development of the combination vaccine for both flu and COVID-19.

As of 2:10 p.m. EDT Tuesday, Novavax stock was trading 7.6% higher, while the broader market indexes were down fractionally.

Taylor Carmichael owns shares of Novavax. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.54 (-2.88%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.